Reactive Oxygen Species-Responsive Delivery of a Notch Inhibitor to Alleviate Nonalcoholic Steatohepatitis by Inhibiting Hepatic de Novo Lipogenesis and Inflammation
Molecular Pharmaceutics · 2024
DOI: 10.1021/acs.molpharmaceut.4c00070 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Pharmaceutics, 2024. Verfasst von Jiahao Chen und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Institute of Metabolic Diseases and Pharmacotherapy, West China Hospital,Sichuan University, Chengdu, Sichuan Province 610041…. Hauptthemen laut MEDLINE: Non-alcoholic Fatty Liver Disease, Reactive Oxygen Species, Nanoparticles, Lipogenesis. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 42 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
With the increased prevalence of nonalcoholic steatohepatitis (NASH) in the world, effective pharmacotherapy in clinical practice is still lacking. Previous studies have shown that dibenzazepine (DBZ), a Notch inhibitor, could alleviate NASH development in a mouse model. However, low bioavailability, poor water solubility, and extrahepatic side effects restrict its clinical application. To overcome these barriers, we developed a reactive oxygen species (ROS)-sensitive nanoparticle based on the conjugation of bilirubin to poly(ethylene glycol) (PEG) chains, taking into account the overaccumulation of hepatic ROS in the pathologic state of nonalcoholic steatohepatitis (NASH). The PEGylated bilirubin can self-assemble into nanoparticles in an aqueous solution and encapsulate insoluble DBZ into its hydrophobic cavity. DBZ nanoparticles (DBZ Nps) had good stability, rapidly released DBZ in response to H2O2, and effectively scavenged intracellular ROS of hepatocytes. After systemic administration, DBZ Nps could accumulate in the liver of the NASH mice, extend persistence in circulation, and improve the bioavailability of DBZ. Furthermore, DBZ Nps significantly improved glucose intolerance, relieved hepatic lipid accumulation and inflammation, and ameliorated NASH-induced liver fibrosis. Additionally, DBZ Nps had no significant extrahepatic side effects. Taken together, our results highlight the potential of the ROS-sensitive DBZ nanoparticle as a promising therapeutic strategy for NASH.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, Institute of Metabolic Diseases and Pharmacotherapy, West China Hospital,Sichuan University, Chengdu, Sichuan Province 610041, China.
ORCID-Profile: Jinhan He
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Chen, J., Zhang, J., Xia, Y., Li, J., Jia, Q., Zhang, Z., Jing, X., Xu, Y., Zou, L., Wang, L., Song, H., Li, J., Liu, Q., Xiong, Y., Tang, Q., Chen, W., Yang, N., Xu, H., Li, Y., & He, J. (2024). Reactive Oxygen Species-Responsive Delivery of a Notch Inhibitor to Alleviate Nonalcoholic Steatohepatitis by Inhibiting Hepatic de Novo Lipogenesis and Inflammation. Molecular Pharmaceutics. https://doi.org/10.1021/acs.molpharmaceut.4c00070
Vancouver
Chen J, Zhang J, Xia Y, Li J, Jia Q, Zhang Z, et al. Reactive Oxygen Species-Responsive Delivery of a Notch Inhibitor to Alleviate Nonalcoholic Steatohepatitis by Inhibiting Hepatic de Novo Lipogenesis and Inflammation. Molecular Pharmaceutics. 2024. doi:10.1021/acs.molpharmaceut.4c00070
BibTeX
@article{Chen2024,
author = {Chen, Jiahao and Zhang, Jinhang and Xia, Yan and Li, Jiahui and Jia, Qingyi and Zhang, Zijing and Jing, Xiandan and Xu, Ying and Zou, Ling and Wang, Lingling and Song, Haiying and Li, Jingwei and Liu, Qinhui and Xiong, Yimin and Tang, Qin and Chen, Wenfei and Yang, Na and Xu, Haixia and Li, Yanping and He, Jinhan},
title = {Reactive Oxygen Species-Responsive Delivery of a Notch Inhibitor to Alleviate Nonalcoholic Steatohepatitis by Inhibiting Hepatic de Novo Lipogenesis and Inflammation},
journal = {Molecular Pharmaceutics},
year = {2024},
doi = {10.1021/acs.molpharmaceut.4c00070}
}
EUVIMED